Cancer Risk in Korean Patients with Gout

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2020 Sep 3

PMID 32872748

Citations 15

Authors

Yoon-Jeong Oh

Yun Jong Lee

Eunyoung Lee

Bumhee Park

Jae-Woo Kwon

Jeongwon Heo

Ki Won Moon

Affiliations

Soon will be listed here.

Abstract

Background/aims: Using a nationwide cohort, we investigated the cancer risk in Korean patients with gout.

Methods: Data were obtained from the Korean National Health Insurance Service Database. Patients with gout were defined as those aged ≥ 20 years who were diagnosed with gout and received anti-gout medication (allopurinol, colchicine, and benzbromarone) between 2008 and 2010. Patients with nail disorders were randomly assigned to a control group (1:1 ratio) after frequency matching for age and sex. Cancer incidence was then investigated between 2012 and 2018. Cox proportional hazard regression analysis was used to investigate the association between gout and cancer after adjusting for concomitant diseases.

Results: This study included 179,930 patients with gout and an equal number of matched controls. The incidence of overall cancer was higher in patients with gout than in controls (incidence rate ratio, 1.08). Cox proportional hazards regression analysis showed that gout was associated with a hazard ratio of 1.053 (95% confidence interval ,1.031 to 1.077) after adjusting for concomitant diseases.

Conclusion: Gout was associated with a significantly high risk of cancer, especially esophageal, stomach, colon, liver, pancreatic, lung, ovarian, renal, and bladder cancers.

Citing Articles

Association between gout and cancers: A systematic review and meta-analysis.

Tian L, Wang Y, Zhang Y, Tian L, Wang H Medicine (Baltimore). 2024; 103(43):e40234.

PMID: 39470515 PMC: 11521056. DOI: 10.1097/MD.0000000000040234.

Causal relationship between genetic-predicted uric acid and cervical cancer risk: evidence for nutritional intervention on cervical cancer prevention.

Cao C, Cai D, Liu H, Zhang X, Cai L, Sun C Front Nutr. 2024; 11:1464046.

PMID: 39371943 PMC: 11449874. DOI: 10.3389/fnut.2024.1464046.

Effect of gout and diabetic kidney disease on renal cancer development in Korea.

Chung S, Jung I, Lee D, Park S, Yu J, Moon J Clin Kidney J. 2024; 17(8):sfae171.

PMID: 39099562 PMC: 11292222. DOI: 10.1093/ckj/sfae171.

Association between serum uric acid and colorectal cancer risk in European population: a two-sample Mendelian randomization study.

Zhou J, Fu R, Zhang J, Zhang S, Lin Z, Lin Z Front Oncol. 2024; 14:1394320.

PMID: 39011473 PMC: 11246881. DOI: 10.3389/fonc.2024.1394320.

The causal relationship of serum uric acid on colorectal cancer: A Mendelian randomization study.

Lee M, Nam S Medicine (Baltimore). 2024; 103(26):e38722.

PMID: 38941363 PMC: 11466122. DOI: 10.1097/MD.0000000000038722.

References

Xie Y, Xu P, Liu K, Lin S, Wang M, Tian T . Hyperuricemia and gout are associated with cancer incidence and mortality: A meta-analysis based on cohort studies. J Cell Physiol. 2019; 234(8):14364-14376. DOI: 10.1002/jcp.28138. View

Strasak A, Lang S, Kneib T, Brant L, Klenk J, Hilbe W . Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 men. Ann Epidemiol. 2008; 19(1):15-24. PMC: 2666912. DOI: 10.1016/j.annepidem.2008.08.009. View

Boffetta P, Nordenvall C, Nyren O, Ye W . A prospective study of gout and cancer. Eur J Cancer Prev. 2009; 18(2):127-32. DOI: 10.1097/CEJ.0b013e328313631a. View

Tu H, Wen C, Tsai S, Chow W, Wen C, Ye Y . Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ. 2018; 360:k134. PMC: 5791146. DOI: 10.1136/bmj.k134. View

Kutzing M, Firestein B . Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2007; 324(1):1-7. DOI: 10.1124/jpet.107.129031. View

Sautin Y, Johnson R . Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6):608-19. PMC: 2895915. DOI: 10.1080/15257770802138558. View

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J . 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707. View

Kuo C, Luo S, See L, Chou I, Fang Y, Yu K . Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine. 2011; 79(4):375-8. DOI: 10.1016/j.jbspin.2011.09.011. View

Kuo C, See L, Yu K, Chou I, Chiou M, Luo S . Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford). 2012; 52(1):127-34. DOI: 10.1093/rheumatology/kes223. View

10.

Wang W, Xu D, Wang B, Yan S, Wang X, Yin Y . Increased Risk of Cancer in relation to Gout: A Review of Three Prospective Cohort Studies with 50,358 Subjects. Mediators Inflamm. 2015; 2015:680853. PMC: 4609488. DOI: 10.1155/2015/680853. View

11.

Chen C, Yen J, Chang S . Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014; 43(5):385-90. DOI: 10.3109/03009742.2013.878387. View

12.

Shih H, Kao M, Tsai P, Fan Y, Huang C . Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Prostate Cancer Prostatic Dis. 2017; 20(3):328-333. DOI: 10.1038/pcan.2017.14. View

13.

Eisenbacher J, Schrezenmeier H, Jahrsdorfer B, Kaltenmeier C, Rojewski M, Yildiz T . S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. J Immunol. 2014; 192(12):6102-10. DOI: 10.4049/jimmunol.1303144. View

14.

Fini M, Elias A, Johnson R, Wright R . Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2013; 1(1):16. PMC: 3560981. DOI: 10.1186/2001-1326-1-16. View

15.

Battelli M, Polito L, Bortolotti M, Bolognesi A . Xanthine oxidoreductase in cancer: more than a differentiation marker. Cancer Med. 2015; 5(3):546-57. PMC: 4799950. DOI: 10.1002/cam4.601. View

16.

Jee S, Lee S, Kim M . Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil. 2004; 11(3):185-91. DOI: 10.1097/01.hjr.0000130222.50258.22. View

17.

Strasak A, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H . Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control. 2007; 18(9):1021-9. DOI: 10.1007/s10552-007-9043-3. View

18.

Strasak A, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H . The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol. 2007; 18(11):1893-7. DOI: 10.1093/annonc/mdm338. View

19.

Chuang J, Lee J, Leu T, Hidajah A, Chang Y, Li C . Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study. BMJ Open. 2019; 9(10):e028892. PMC: 6797386. DOI: 10.1136/bmjopen-2019-028892. View